gluconeogenic inhibitor 3 mpa (MedChemExpress)
MedChemExpress is a verified supplier 
MedChemExpress manufactures this product 
94
Structured Review
MedChemExpress
gluconeogenic inhibitor 3 mpa
Gluconeogenic Inhibitor 3 Mpa, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 18 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/3+mpa/Mpa/pmc12811904-70-16-19
Average 94 stars, based on 18 article reviews
Gluconeogenic Inhibitor 3 Mpa, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 18 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/3+mpa/Mpa/pmc12811904-70-16-19
Average 94 stars, based on 18 article reviews
gluconeogenic inhibitor 3 mpa - by Bioz Stars,
2026-10
94/100 stars
Images
1) Product Images from "METTL3 regulates Leydig cell proliferation via miR-145-PCK1 mediated gluconeogenesis in goats"
Article Title: METTL3 regulates Leydig cell proliferation via miR-145-PCK1 mediated gluconeogenesis in goats
Journal: Journal of Animal Science and Biotechnology
doi: 10.1186/s40104-025-01307-5
Figure Legend Snippet: METTL3 regulates goat LC proliferation through the glyconeogenesis pathway. A Cell viability of LCs treated with siMETTL3 and siMETTL3+3-MPA group ( n = 5). B LCs were treated with siMETTL3 and siMETTL3+3-MPA, and EdU (green) was used to label the proliferating cells. The cell nuclei were counterstained with DAPI ( n = 4). Scale bar: 100 μm. C Lactic acid level of LCs treated with siNC and siMETTL3+3-MPA for 24 h ( n = 4). D Glucose level of LCs treated with siMETTL3 and siMETTL3+3-MPA for 24 h ( n = 4). E Glucose uptake ability of LCs treated with siMETTL3 and siMETTL3+3-MPA, assessed using immunofluorescence and quantitative analysis ( n = 4). Scale bar: 100 μm. F – G Changes in mitochondrial membrane potential in LCs treated with siMETTL3 and siMETTL3+3-MPA were analyzed by JC-1 staining and the fluorescence intensity of JC-1 aggregates/monomers was quantified ( n = 4). Scale bar: 100 μm. H The relative mRNA expression levels of METTL3 , PCK1 , CCNB1 and CCNE2 treated with siMETTL3 and siMETTL3+3-MPA ( n = 3). I – J The levels of METTL3, PCK1, CCNB1, CCNE2 and β-actin were assessed via Western blotting. Relative protein levels were analysed via gray scanning ( n = 3). * P < 0.05, ** P < 0.01
Techniques Used: Immunofluorescence, Membrane, Staining, Fluorescence, Expressing, Western Blot
Figure Legend Snippet: miR-145-3p regulates goat LC proliferation through the glyconeogenesis pathway. A Cell viability of LCs treated with Mimics-NC and Mimics-145-3p ( n = 5). B LCs were treated with Mimics-NC and Mimics-145-3p, and EdU (green) was used to label the proliferating cells. The cell nuclei were counterstained with DAPI ( n = 4). Scale bar: 100 μm. C Glucose level of LCs treated with Mimics-NC and Mimics-145-3p ( n = 4). D Lactic acid level of LCs treated with Mimics-NC and Mimics-145-3p ( n = 4). E – F Glucose uptake ability of LCs treated with Mimics-NC and Mimics-145-3p, assessed using immunofluorescence and quantitative analysis ( n = 4). Scale bar: 100 μm. G – H Changes in mitochondrial membrane potential in LCs treated with Mimics-NC and Mimics-145-3p were analyzed by JC-1 staining and the fluorescence intensity of JC-1 aggregates/monomers was quantified ( n = 4). Scale bar: 100 μm. I The relative mRNA expression levels of PCK1 , CCNB1 and CCNE2 treated with Mimics-NC and Mimics-145-3p ( n = 3). J – K The levels of PCK1, CCNB1, CCNE2 and β-actin were assessed via Western blotting. Relative protein levels were analysed via gray scanning ( n = 3). L Cell viability of LCs treated with Inhibitor-145-3p and Inhibitor-145-3p+3-MPA ( n = 5). M LCs were treated with Inhibitor-145-3p and Inhibitor-145-3p+3-MPA, and EdU (green) was used to label the proliferating cells. The cell nuclei were counterstained with DAPI ( n = 4). Scale bar: 100 μm. N Glucose level of LCs treated with Inhibitor-145-3p and Inhibitor-145-3p+3-MPA ( n = 4). O Lactic acid level of LCs treated with Inhibitor-145-3p and Inhibitor-145-3p+3-MPA ( n = 4). P – Q Glucose uptake ability of LCs treated with Inhibitor-145-3p and Inhibitor-145-3p+3-MPA, assessed using immunofluorescence and quantitative analysis ( n = 4). Scale bar: 100 μm. R – S Changes in mitochondrial membrane potential in LCs treated with Inhibitor-145-3p and Inhibitor-145-3p+3-MPA were analyzed by JC-1 staining and the fluorescence intensity of JC-1 aggregates/monomers was quantified ( n = 4). Scale bar: 100 μm. T The relative mRNA expression levels of CCNB1 and CCNE2 treated with Inhibitor-145-3p and Inhibitor-145-3p+3-MPA ( n = 3). U – V The levels of PCK1, CCNB1, CCNE2 and β-actin were assessed via Western blotting. Relative protein levels were analysed via gray scanning ( n = 3). * P < 0.05, ** P < 0.01
Techniques Used: Immunofluorescence, Membrane, Staining, Fluorescence, Expressing, Western Blot
Figure Legend Snippet: PCK1 regulates goat Leydig cell proliferation through the gluconeogenesis pathway. A The relative mRNA expression levels of PCK1 , CCNB1 and CCNE2 treated with OE-NC and OE-PCK1 ( n = 3). B – C The levels of PCK1, CCNB1, CCNE2 and β-actin were assessed via Western blotting. Relative protein levels were analysed via gray scanning ( n = 3). D The relative mRNA expression levels of PCK1 , CCNB1 and CCNE2 treated with siNC and siPCK1 ( n = 3). E – F The levels of PCK1, CCNB1, CCNE2 and β-actin were assessed via Western blotting. Relative protein levels were analysed via gray scanning ( n = 3). G Cell viability of LCs treated with OE-PCK1 and OE-PCK1+3-MPA group ( n = 5). H LCs were treated with OE-PCK1 and OE-PCK1+3-MPA group, and EdU (green) was used to label the proliferating cells. The cell nuclei were counterstained with DAPI ( n = 4). Scale bar: 100 μm. I Glucose level of LCs treated with OE-PCK1 and OE-PCK1+3-MPA ( n = 4). J Lactic acid of LCs treated with OE-PCK1 and OE-PCK1+3-MPA ( n = 4). K–L Glucose uptake ability of LCs treated with OE-PCK1 and OE-PCK1+3-MPA, assessed using immunofluorescence and quantitative analysis ( n = 4). Scale bar: 100 μm. M–N Changes in mitochondrial membrane potential in LCs treated with OE-PCK1 and OE-PCK1+3-MPA were analyzed by JC-1 staining and the fluorescence intensity of JC-1 aggregates/monomers was quantified ( n = 4). Scale bar: 100 μm. O The relative mRNA expression levels of CCNB1 and CCNE2 treated with OE-PCK1 and OE-PCK1+3-MPA ( n = 3). P – Q The levels of PCK1, CCNB1, CCNE2 and β-actin were assessed via Western blotting. Relative protein levels were analysed via gray scanning ( n = 3). * P < 0.05, ** P < 0.01
Techniques Used: Expressing, Western Blot, Immunofluorescence, Membrane, Staining, Fluorescence
Related Articles
other:Article Title: PCK2 induces gefitinib resistance by suppresses ferroptosis in non-small cell lung cancer. Article Snippet: Objectives: This study aimed to explore the involvement of phosphoenolpyruvate carboxykinase 2 (PCK2) in gefitinib-resistant non-small cell lung cancer (NSCLC) cells and assess its feasibility as a therapeutic target against gefitinib resistance.. Methods: Gefitinib-resistant cell lines, PC9GR and HCC827GR, were generated through progressive exposure of parental cells to escalating concentrations of gefitinib.. Transcriptomic analysis encompassed the treatment of PC9 and PC9GR cells with gefitinib or vehicle, followed by RNA extraction, sequencing, and subsequent bioinformatic analysis. Article Title: Overcoming Chemoresistance to Vemurafenib in Melanoma via Targeted Inhibition of PCK1 Using 3-mercaptopropionic Acid Article Snippet: The parallel group design was adopted, and the mice were treated with 30 mg/kg Fat:Article Title: Metabolic switch from glycogen to lipid in the liver maintains glucose homeostasis in neonatal mice. Article Snippet: .. Fat emulsion feeding and glucose injection From 6 h after birth, the pups lactated by Cidea−/− females (low-fat milk, LFM) were orally administrated with 25 μl/g (body weight) of 20% (w/w) fat emulsion, which contains soybean oil, 20% (w/v); lecithin, 1.2% (w/v); and glycerol, 2.2% (w/v) that was orally supplemented every 6 h. Or the pups were injected with 50 μl/g of 5% glucose in PBS every 8 h. Pent-4-enoate (fatty acid oxidation [FAO] inhibitor, Selleck, 2 mg/g body weight) or Emulsion:Article Title: Metabolic switch from glycogen to lipid in the liver maintains glucose homeostasis in neonatal mice. Article Snippet: .. Fat emulsion feeding and glucose injection From 6 h after birth, the pups lactated by Cidea−/− females (low-fat milk, LFM) were orally administrated with 25 μl/g (body weight) of 20% (w/w) fat emulsion, which contains soybean oil, 20% (w/v); lecithin, 1.2% (w/v); and glycerol, 2.2% (w/v) that was orally supplemented every 6 h. Or the pups were injected with 50 μl/g of 5% glucose in PBS every 8 h. Pent-4-enoate (fatty acid oxidation [FAO] inhibitor, Selleck, 2 mg/g body weight) or Article Title: Metabolic switch from glycogen to lipid in the liver maintains glucose homeostasis in neonatal mice Article Snippet: .. From 6 h after birth, the pups lactated by Cidea −/− females (low-fat milk, LFM) were orally administrated with 25 μl/g (body weight) of 20% (w/w) fat emulsion, which contains soybean oil, 20% (w/v); lecithin, 1.2% (w/v); and glycerol, 2.2% (w/v) that was orally supplemented every 6 h. Or the pups were injected with 50 μl/g of 5% glucose in PBS every 8 h. Pent-4-enoate (fatty acid oxidation [FAO] inhibitor, Selleck, 2 mg/g body weight) or Injection:Article Title: Metabolic switch from glycogen to lipid in the liver maintains glucose homeostasis in neonatal mice. Article Snippet: .. Fat emulsion feeding and glucose injection From 6 h after birth, the pups lactated by Cidea−/− females (low-fat milk, LFM) were orally administrated with 25 μl/g (body weight) of 20% (w/w) fat emulsion, which contains soybean oil, 20% (w/v); lecithin, 1.2% (w/v); and glycerol, 2.2% (w/v) that was orally supplemented every 6 h. Or the pups were injected with 50 μl/g of 5% glucose in PBS every 8 h. Pent-4-enoate (fatty acid oxidation [FAO] inhibitor, Selleck, 2 mg/g body weight) or Article Title: Metabolic switch from glycogen to lipid in the liver maintains glucose homeostasis in neonatal mice Article Snippet: .. From 6 h after birth, the pups lactated by Cidea −/− females (low-fat milk, LFM) were orally administrated with 25 μl/g (body weight) of 20% (w/w) fat emulsion, which contains soybean oil, 20% (w/v); lecithin, 1.2% (w/v); and glycerol, 2.2% (w/v) that was orally supplemented every 6 h. Or the pups were injected with 50 μl/g of 5% glucose in PBS every 8 h. Pent-4-enoate (fatty acid oxidation [FAO] inhibitor, Selleck, 2 mg/g body weight) or Mouse Assay:Article Title: Measurement of gluconeogenesis by 2 H 2 O labeling and mass isotopomer distribution analysis Article Snippet: .. Mice were treated with Article Title: Measurement of gluconeogenesis by 2 H 2 O labeling and mass isotopomer distribution analysis. Article Snippet: .. 3-MPA administration Mice were treated with |